Last reviewed · How we verify
Chemotherapy and target therapy
Chemotherapy and target therapy is a Small molecule drug developed by Haining Health-Coming Biotech Co., Ltd.. It is currently in Phase 2 development.
At a glance
| Generic name | Chemotherapy and target therapy |
|---|---|
| Sponsor | Haining Health-Coming Biotech Co., Ltd. |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- A Study of Targeted Radiation Therapy in People With Non-Small Cell Lung Cancer (NSCLC) (PHASE2)
- BLAST MRD AML-2: BLockade of PD-1 Added to Standard Therapy to Target Measurable Residual Disease in Acute Myeloid Leukemia 2- A Randomized Phase 2 Study of Anti-PD-1 Pembrolizumab in Combination With Azacitidine and Venetoclax as Frontline Therapy in Unfit Patients With Acute Myeloid Leukemia (PHASE2)
- Virotherapy and Natural History Study of KHSV-Associated Multricentric Castleman s Disease With Correlates of Disease Activity (PHASE2)
- Pediatric-Inspired Regimen Combined With Venetoclax and Immunotherapy for Adult Ph-Negative Acute Lymphoblastic Leukemia (NA)
- Study Evaluating the Safety and Efficacy of HWK-007, a PTK7-directed Antibody Drug Conjugate in Participants With Advanced Solid Tumors (PHASE1)
- A Study of NX-5948 in Adults With Relapsed/Refractory B-cell Malignancies (PHASE1)
- MP0317 in Combination With Chemoimmunotherapy in First Line Treatment for Patients With Advanced Biliary Tract Carcinoma (PHASE2)
- MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial) (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Chemotherapy and target therapy CI brief — competitive landscape report
- Chemotherapy and target therapy updates RSS · CI watch RSS
- Haining Health-Coming Biotech Co., Ltd. portfolio CI
Frequently asked questions about Chemotherapy and target therapy
What is Chemotherapy and target therapy?
Chemotherapy and target therapy is a Small molecule drug developed by Haining Health-Coming Biotech Co., Ltd..
Who makes Chemotherapy and target therapy?
Chemotherapy and target therapy is developed by Haining Health-Coming Biotech Co., Ltd. (see full Haining Health-Coming Biotech Co., Ltd. pipeline at /company/haining-health-coming-biotech-co-ltd).
What development phase is Chemotherapy and target therapy in?
Chemotherapy and target therapy is in Phase 2.